Clinical trials: Migraine, Acute
Migraine, With or Without Aura
Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults
The purpose of this study is to evaluate the long-term safety of BR005-036C tablets in the acute treatment of migraines
- Trial name
- NCT07835152
- Testing
- BR005-036C
- Where
- 81 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.
Migraine
A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
This study will provide additional efficacy data for rizatriptan when used for an acute migraine attack in patients already taking topiramate for migraine prophylaxis.
- Trial name
- NCT00812006
- Testing
- rizatriptan benzoate
- Volunteers
- 108 people
- Sponsor
- Organon and Co
Migraine
Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)
Migraine is a prevalent neurological disorder that severely impacts both children and adolescents, causing significant disability.
- Trial name
- NCT06138756
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 293 people
- Sponsor
- Theranica
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: Subject self-examination skin irritation scores Adverse events Changes in vital signs and ECG parameters The secondary objective is…
- Trial name
- NP101-008 (NCT00792103)
- Testing
- NP101
- Where
- 34 sites in United States
- Volunteers
- 198 people
- Sponsor
- NuPathe Inc.
Migraine
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
- Trial name
- NCT07816367
- Testing
- Elismetrep
- Where
- 72 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- TriGemX Bio, Inc.
Acute Migraine
Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine
This will be a Phase 1, multiple center, open label, single-dose study in otherwise healthy adolescent subjects with a history of acute migraine. Subjects will each receive one Zecuity patch application.
- Trial name
- NCT02684409
- Testing
- PROT-CL-NP101-015.01
- Volunteers
- 37 people
- Sponsor
- NuPathe Inc.
Migraine Disorders, Migraine
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO.
- Trial name
- NCT00319137
- Testing
- GW274150
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders, Heart Disease
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease.
- Conditions
- Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack)
- Trial name
- NCT00662818
- Testing
- Telcagepant, Acetaminophen/Paracetamol
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Headaches
Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
This is a Phase 1/ Phase 2, 12-week, multi-center, randomized, double-blind, cross-over, placebo-controlled study to evaluate the efficacy and safety of ELS-M11 compared to placebo in 50 male and female subjects, aged 18 to 65…
- Trial name
- NCT02057315
- Testing
- ELS-M11
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Achelios Therapeutics
Migraine
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- UBRO PEDS OLE (NCT05127954)
- Testing
- Ubrogepant
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 1,200 people
- Sponsor
- AbbVie
Acute Migraine With or Without Aura in Adolescents
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17…
- Trial name
- NCT01004263
- Testing
- rizatriptan benzoate
- Volunteers
- 674 people
- Sponsor
- Organon and Co
Acute Migraine
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine
- Trial name
- NCT04218162
- Testing
- Lasmiditan 50mg, Lasmiditan 100mg
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Migraine in Adolescence
Real-world Data Analysis of REN Treatment in Adolescence With Migraine
This is a Post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, Israel) in adolescents with migraine.
- Trial name
- NCT05443659
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 1,629 people
- Sponsor
- Theranica
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Migraine
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101.
- Trial name
- NCT06728553
- Testing
- MTX101
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Manistee Therapeutics
Migraine Disorders
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.
- Trial name
- NCT00963937
- Testing
- Sumatriptan 25 mg, Sumatriptan 50 mg
- Where
- 16 sites in Japan
- Volunteers
- 178 people
- Sponsor
- GlaxoSmithKline
Migraine
Consistency of Response With Rimegepant in Acute Treatment of Migraine
This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks.
- Trial name
- CORRELATE-UK (NCT06898047)
- Testing
- Rimegepant for acute migraine treatment
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Pfizer
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE I (NCT02828020)
- Testing
- Ubrogepant
- Where
- 90 sites in United States
- Volunteers
- 1,672 people
- Sponsor
- Allergan
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Migraine Disorders
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
- Trial name
- NCT00240617
- Testing
- sumatriptan succinate/naproxen sodium
- Where
- 52 sites in United States
- Volunteers
- 623 people
- Sponsor
- GlaxoSmithKline